Figure 1 | Scientific Reports

Figure 1

From: Smartphone-enabled optofluidic exosome diagnostic for concussion recovery

Figure 1

Rapid exosome-based prognosis of mild traumatic brain injury (mTBI) on a microchip.

(a) We developed a microfluidic-based platform to isolate and profile brain-derived exosomes to diagnose mild traumatic brain injury (mTBI). Following mTBI, brain-derived exosomes (pink) that carry molecular information from their mother cells circulate in the blood amongst a vast background exosomes (blue). (b) The results, from serum to a digital read out, are automated on the microchip platform and can be carried out in less than 1 hour, empowering healthcare providers with real-time molecular information at the point of medical care. (c) On our microchip, first CD45 and CD61 coated functionalized microbeads are used to negatively select exosomes from abundant cell types (leukocytes, platelets) prior to positive selection to diminish background, which would otherwise limit sensitivity. (d) CD81 (a pan-exosome marker) functionalized microbeads are then used to capture the remaining exosomes. (e) These isolated exosomes are labeled with GluR2 antibodies, functionalized with the catalyst Horseradish Peroxidase (HRP). (f) The presence of HRP on these microbeads, leads to the enzymatic generation of fluorescent dye, which can be easily detected by our smartphone based fluorescence detection.

Back to article page